Recent Updates
Recently added Catalysts
IMVT Positive Sentiment Score: 70/100

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Friday, January 23, 2026 1 min read
Key Takeaway: Immunovant has announced it will report its financial results for the third quarter ending December 31, 2025, along with a business update on February 6, 2026. The event is scheduled for 8:00 a.m. ET and will be accessible via a conference call and webcast. The company continues to focus on developing innovative immunology treatments, particularly using its anti-FcRn technology to address autoimmune diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunovant is on track to report its financial results, indicating operational progress.
  • The company's focus on anti-FcRn technology signifies innovation in treatment for autoimmune diseases.
  • The upcoming business update suggests proactive communication with stakeholders.

Full Press Release Details

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
keyur.parekh@roivant.com
stephanie.lee@roivant.com

Frequently Asked Questions

When does Immunovant report its Q3 financial results?

Immunovant will report its Q3 financial results on February 6, 2026.

How can I access the Immunovant conference call?

You can access the call by registering online through the provided link.

Where to find the archived webcast of the conference?

The archived webcast will be available on Immunovant's website post-call.

What type of company is Immunovant?

Immunovant is a clinical-stage immunology company focused on autoimmune diseases.

What is Immunovant's focus in therapy development?

The company develops innovative therapies using anti-FcRn technology for autoimmune diseases.

Tags: IMVT Viatris Investor Conferences Healthcare Immunovant autoimmune diseases financial results anti-FcRn technology Nasdaq
Last updated: Jan 23, 2026